Jean Stephenne
Chairman at TIGENIX NV
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Baron Jean Stéphenne | M | 73 |
Vaxxilon AG
Vaxxilon AG BiotechnologyHealth Technology Part of Johnson & Johnson, Vaxxilon AG is a Swiss company that develops and manufactures novel synthetic vaccines. The company is based in Reinach, Switzerland.
BePharBel Manufacturing SA
BePharBel Manufacturing SA Pharmaceuticals: MajorHealth Technology BePharBel Manufacturing SA manufactures and distributes pharmaceutical products. Its products include drugs, tuberculosis and food supplements and cosmetics. The company was founded on March 26, 2012 and is headquartered in Courcelles, Belgium.
OncoDNA SA
OncoDNA SA Medical/Nursing ServicesHealth Services OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium.
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 years |
Jean-Pol Detiffe | M | 51 |
OncoDNA SA
OncoDNA SA Medical/Nursing ServicesHealth Services OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium. | 12 years |
Ingmar Hoerr | M | - |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | - |
Francois Rieger | M | - | - | |
Florian von der Muelbe | M | 52 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 24 years |
Wilfried Dalemans | M | 66 | - | |
Antoine de Mortemart | M | - |
BePharBel Manufacturing SA
BePharBel Manufacturing SA Pharmaceuticals: MajorHealth Technology BePharBel Manufacturing SA manufactures and distributes pharmaceutical products. Its products include drugs, tuberculosis and food supplements and cosmetics. The company was founded on March 26, 2012 and is headquartered in Courcelles, Belgium. | - |
Yves Sagot | M | 60 | 1 years | |
Friedrich von Bohlen und Halbach | M | 60 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | - |
Véronique Pomi-Schneiter | F | - | - | |
Revital Rattenbach | M | - | - | |
Nicco Carole | M | - | 1 years | |
Jacques Reymann | M | - |
BePharBel Manufacturing SA
BePharBel Manufacturing SA Pharmaceuticals: MajorHealth Technology BePharBel Manufacturing SA manufactures and distributes pharmaceutical products. Its products include drugs, tuberculosis and food supplements and cosmetics. The company was founded on March 26, 2012 and is headquartered in Courcelles, Belgium. | - |
Cyril Wolkonsky | M | - |
BePharBel Manufacturing SA
BePharBel Manufacturing SA Pharmaceuticals: MajorHealth Technology BePharBel Manufacturing SA manufactures and distributes pharmaceutical products. Its products include drugs, tuberculosis and food supplements and cosmetics. The company was founded on March 26, 2012 and is headquartered in Courcelles, Belgium. | - |
Olivier de Duve | M | - |
OncoDNA SA
OncoDNA SA Medical/Nursing ServicesHealth Services OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium. | - |
Debra Stephanie Barker | M | 61 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | - |
Sebastian Wehle | M | - | 6 years | |
Jean-Michel Verhaegen | M | - |
OncoDNA SA
OncoDNA SA Medical/Nursing ServicesHealth Services OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium. | - |
Igor Splawski | M | 56 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 4 years |
Bernd Winterhalter | M | 65 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 5 years |
Gery Lefebvre | M | - |
OncoDNA SA
OncoDNA SA Medical/Nursing ServicesHealth Services OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium. | - |
Thierry Coche | M | - |
OncoDNA SA
OncoDNA SA Medical/Nursing ServicesHealth Services OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium. | - |
Alain Declercq | M | 44 |
OncoDNA SA
OncoDNA SA Medical/Nursing ServicesHealth Services OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium. | - |
Julian Panes | M | - | - | |
Lieven Huysse | M | - | 1 years | |
Alexia Rieger | F | - | - | |
An Herremans | F | 42 |
OncoDNA SA
OncoDNA SA Medical/Nursing ServicesHealth Services OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium. | - |
Ralf Clemens | M | 71 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 8 years |
Timothy M. Wright | M | 69 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 5 years |
Jean-François Rax | M | - | - | |
Michael Brosnan | M | 69 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | - |
Simon Buckingham | M | 60 |
Vaxxilon AG
Vaxxilon AG BiotechnologyHealth Technology Part of Johnson & Johnson, Vaxxilon AG is a Swiss company that develops and manufactures novel synthetic vaccines. The company is based in Reinach, Switzerland. | - |
Maria Pascual | M | - | - | |
Hans Tanner | M | 72 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 years |
François Fontaine | M | - |
OncoDNA SA
OncoDNA SA Medical/Nursing ServicesHealth Services OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium. | - |
Anne Prignon | F | - |
BePharBel Manufacturing SA
BePharBel Manufacturing SA Pharmaceuticals: MajorHealth Technology BePharBel Manufacturing SA manufactures and distributes pharmaceutical products. Its products include drugs, tuberculosis and food supplements and cosmetics. The company was founded on March 26, 2012 and is headquartered in Courcelles, Belgium. | - |
William Rhodes | M | 70 |
OncoDNA SA
OncoDNA SA Medical/Nursing ServicesHealth Services OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium. | - |
John Eric F. P. C. Bertrand | M | 46 |
OncoDNA SA
OncoDNA SA Medical/Nursing ServicesHealth Services OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium. | - |
Pierre Kemula | M | 50 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 8 years |
Ulrike Gnad-Vogt | M | - |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 13 years |
Bernard Courtieu | M | 60 |
OncoDNA SA
OncoDNA SA Medical/Nursing ServicesHealth Services OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium. | 3 years |
François Blondel | M | 60 |
OncoDNA SA
OncoDNA SA Medical/Nursing ServicesHealth Services OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium. | - |
Micheline Streel | F | 60 |
OncoDNA SA
OncoDNA SA Medical/Nursing ServicesHealth Services OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium. | - |
Jean-Luc Vandebroek | M | 53 | - | |
Mathias Hothum | M | 58 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | - |
Mary Carmen Diez | M | - | 10 years | |
Craig Tooman | M | 58 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 5 years |
Mariola Fotin-Mleczek | M | 50 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 18 years |
Koen Huygens | M | - | 23 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Belgium | 33 | 67.35% |
Germany | 16 | 32.65% |
Switzerland | 2 | 4.08% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jean Stephenne
- Personal Network